Science Publications

Sign Up
Sign In
Submit
World Journal of Cancer and Oncology Research
Download PDF XML
  1. Home
  2. Journals
  3. World Journal of Cancer and Oncology Research
  4. Archive
  5. Volume 3, Number 1, 2024
  6. Article
  7. Table 1

Mutational Analysis of Driver and Non-driver Mutations of Philadelphia Chromosome-negative Myeloproliferative Neoplasms; Diagnosis and Recent Advances in Treatment

Table 1.

Simplified 2022 WHO diagnosis criteria for PVand post-PV MF; Adapted from: [6, 104].
PV Post-PV MF
Major Criteria: Required Criteria:
Elevated hemoglobin > 18.5 g/dL in men, 16.5 g/dL in women, or increased hematocrit (> 49% in men, > 48% in women)+ Previously diagnosed PV
Presence of JAK2 V617F or Exon 12 mutation (< 1% sensitivity). Grade 2 or 3 bone marrow fibrosis.
Hypercellular bone marrow with trilineage proliferation, including prominent erythroid, granulocytic and increased pleomorphic, mature megakaryocytes without atypia. Additional Criteria:
Minor Criteria: Anemia
Subnormal erythropoietin level Leukoerythroblastosis.
Requirements for diagnosis: New or increased palpable splenomegaly >5 cm from baseline
All 3 major OR first 2 major + minor criterion* Presence of at least 2 of the following: unexplained pyrexia (>37.5℃), weight loss (>10% in 6 months), night sweats.
  Requirement for diagnosis:
  All required criteria + 2 or more additional criteria

+As a refinement to the 2016 WHO diagnostic criteria, increased red cell mass has been removed as a major criterion

*Major criterion 3 may not be required in patients with sustained absolute erythrocytosis: hemoglobin >18.5 g/dL and hematocrit >55.5% in men or hemoglobin >16.5 g/dL and hematocrit, 49.5% in women; if major criterion 2 and the minor criterion are present.